Transplanting an entire human eye is one of medicine’s moonshots, and not just because the surgery is brutally delicate. The bigger problem is time: once an eye is removed, its tissues, especially the retina, start breaking down fast.
Now a team in Spain says it has built a device that can “perfuse” eyes from deceased donors, pumping them with oxygen and nutrients to mimic blood flow and slow that rapid decay. The work is early and posted as a preprint, meaning it hasn’t yet been vetted through peer review. But if the results hold up, the technology could expand what surgeons and researchers can do with donor eyes, even before whole-eye transplants become realistic.
A “care box” for eyes, built to buy precious time
Sommaire
The device is called the Eye-in-a-Care-Box, or ECaBox. It was developed by researcher Pia Cosma at the Centre for Genomic Regulation, part of the Barcelona Institute of Science and Technology, one of Spain’s major biomedical research hubs.
The concept borrows from organ transplantation, where perfusion systems are already used to keep hearts, livers, and kidneys viable outside the body. For eyes, the goal is straightforward: deliver oxygen and nutrients through the artery that normally supplies the eye, while flushing out waste products that build up after death.
The eye sits on a support inside a sealed chamber designed to hold steady temperature and pressure. A transparent side window allows imaging and observation without opening the system, important because every interruption can destabilize the conditions keeping the tissue functional.
Why the retina is the make-or-break tissue
The retina is neural tissue, an extension of the central nervous system, and it’s extremely sensitive to oxygen deprivation. Once it degrades, the eye may still look intact, but the machinery that converts light into electrical signals can fail.
That’s why researchers focus on whether the retina can still generate electrical activity, including responses to light. Those signals are a prerequisite for vision, even though they’re not the same thing as a person actually seeing.
Shannon Tessier, a Massachusetts General Hospital specialist who works on perfusion in other organs and was not involved in the study, called the approach a “new frontier” for preserving the retina, an assessment that reflects how quickly eye tissue typically becomes unusable after removal.
Pig-eye tests suggest perfusion beats cold storage
To develop ECaBox, the team first ran experiments on pig eyes, commonly used in vision research because their anatomy is relatively similar to humans’. The eyes came from a local slaughterhouse, allowing repeated trials while the system was refined.
According to the researchers, eyes left at room temperature deteriorated quickly. They also tested cold storage, standard practice for many tissues, but reported that chilling didn’t adequately protect the eye. Even at about 39°F (4°C), the tissue still degenerated in under 24 hours.
Eyes kept in the perfusion device, by contrast, were described as “significantly more viable” after 24 hours than non-perfused controls. The preprint excerpt does not fully detail every measurement method, but the central claim is based on direct comparisons between perfused eyes and eyes stored without the system.
The team also reported a functional marker: light response. Untreated pig eyes lost that response immediately after removal, the researchers said. With perfusion, the response reportedly returned after about 15 minutes and, in some cases, persisted for 10 hours or more.
Human donor eyes: 12 eyes from six people, paired against controls
After the pig experiments, the researchers tested ECaBox on human eyes recovered after death: 12 eyes from six donors. For each donor, one eye went into the device and the other served as a control, an approach that helps reduce differences tied to age, vascular health, medical history, and recovery conditions.
The available source text cuts off before providing detailed results from the human-eye measurements, limiting what can be said about how well the system preserved function in those samples. The stated aim was to see whether perfusion could maintain viability markers and, ideally, signals consistent with preserved retinal activity.
The authors have not commented publicly on the work, and because the findings are still a preprint, independent replication and full methodological transparency will be crucial before anyone draws clinical conclusions.
Why whole-eye transplants still aren’t around the corner
Keeping an eye viable is only one piece of the puzzle. The hardest barrier to restoring sight after a whole-eye transplant is the optic nerve, the cable that carries visual information to the brain. Unlike blood vessels, nerve fibers can’t simply be stitched back together, and meaningful regeneration in humans remains limited.
That’s why previous attempts at whole-eye transplantation have not restored vision, even when the transplanted eye survived anatomically. A perfusion device could reduce damage caused by time outside the body, improving the starting conditions, but it doesn’t solve the neurological bottleneck.
Even the most encouraging lab readouts, like a retina responding to light, don’t automatically translate into perception. To move from promising preservation to functional transplantation, researchers would need standardized measures of electrical signaling, evidence those signals can travel through repaired pathways, and safe surgical protocols that can be reproduced across centers.
If ECaBox holds up under peer review, its near-term impact may be less about headline-grabbing eye transplants and more about expanding research: giving scientists a longer window to study human retinal disease, test repair strategies, and refine surgical techniques using tissue that behaves more like it does in the living body.
